Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/MGTA · Entity 1813 | See Remarks | August 01, 2022 | August 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dianthus Therapeutics, Inc. /DE/
Report date August 01, 2022 · Filed August 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.57 · Expires 2032-07-31 | Direct | 100,000 |
Reported balance
After 2022-08-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 100,000 · Balance 100,000 F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2022 Filed Aug 2, 2022 01:18 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.57 | $0.00 |
DisclosureSEC source: 0000899243-22-027275 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-07-31 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:24 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.18 | $0.00 |
DisclosureSEC source: 0000899243-22-018822 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-05-16 F1 · derivative.exercise_date: This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 22:17 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.19 | $0.00 |
DisclosureSEC source: 0000899243-22-006815 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 21:00 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | SaleCommon Stock | 5,736 | $6.73 | $38,603.28 |
DisclosureSEC source: 0000899243-21-036596 · doc4.xml · nonDerivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,264 F1 · kind: This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 23:43 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-036342 · doc4.xml · nonDerivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: On February 11, 2021, the reporting person was granted 40,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 20,000 restricted stock units and the corresponding issuance of 20,000 shares of issuer common stock. Read SEC document |
| August 02, 2021 Filed Aug 3, 2021 20:39 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $7.11 | $0.00 |
DisclosureSEC source: 0000899243-21-031275 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-08-01 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on August 2, 2021. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 20:36 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.90 | $0.00 |
DisclosureSEC source: 0000899243-21-029470 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-07-19 F1 · derivative.exercise_date: This option shall vest and become exercisable over four years, with 25% of this option vesting on July 20, 2022, and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 22:58 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0000899243-21-006727 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-02-10 F1 · derivative.exercise_date: This option shall vest and become exercisable in 16 equal quarterly installments beginning on January 1, 2021. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:37 UTC | Dianthus Therapeutics, Inc. /DE/ MGTA · Entity 1813 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000899243-20-025332 · doc4.xml · derivative · entry 1 Olson Lisa · CIK 0001824009 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-09-13 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on September 14, 2021, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.